KR20240000170A - Composition for regulating Biofilm formation of Cutibacterium sp. comprising Sorbitan caprylate - Google Patents

Abstract

The present invention relates to a composition for controlling biofilm formation of Cutibacterium sp., a cosmetic composition for maintaining microbiome balance, and a quasi-drug composition containing sorbitan caprylate as an active ingredient,
A composition containing sorbitan caprylate as an active ingredient regulates the biofilm formation of Cutibacterium strains, thereby maintaining the skin microbiome balance, making it safe for the skin and used as a cosmetic composition and quasi-drug composition with excellent skin condition improvement effects. It can be.

Description

Composition for regulating biofilm formation of Cutibacterium strains containing sorbitan caprylate {Composition for regulating Biofilm formation of Cutibacterium sp. comprising Sorbitan caprylate}

The present invention provides a composition for controlling biofilm formation of Cutibacterium sp. containing sorbitan caprylate as an active ingredient, a cosmetic composition, a quasi-drug composition, and maintaining the microbiome balance of Cutibacterium strains. It relates to a cosmetic composition for use.

Microorganisms' biofilms are their own way of life to adapt to the environment. Biofilms formed by microorganisms are strongly attached to various surfaces and are difficult to remove, and have much stronger resistance to harsh environments (e.g. pH, temperature, depletion of nutrients, etc.) and antibiotic attacks than when living in a floating environment. Because it has sterilization and disinfection, it is difficult.

Additionally, because microorganisms can obtain various benefits as a result of the formation of such biofilms, they exist in the form of biofilms in most natural and industrial environments. Microorganisms that form biofilms exist fixed to the surface, covered with a polymer substance secreted externally by individual microorganisms called EPS (extracellular polymeric substance; Carbohydrate, Protein, and Nucleic acid). Therefore, biofilm is a film in which microorganisms such as bacteria, yeast, and mold attach to the surface of the human body (e.g., skin, oral cavity, teeth, etc.) or facilities (e.g., pipes, storage tanks, etc.) under certain conditions. It can be said to be a collection of microorganisms, and it itself serves as a habitat for microorganisms, accelerating the growth of bacteria. Since these microorganisms in biofilms can cause serious problems throughout industry and medicine, research on compositions for removing or inhibiting the formation of biofilms and methods for inhibiting or removing biofilm formation is required.

In particular, the outer matrix of the biofilm, which is densely packed with hydrogen bonds of polysaccharides, prevents antibacterial agents from penetrating into the inside, thereby hindering the action of antibacterial agents. Therefore, to remove the biofilm, strong acid/strong base treatment or direct physical scraping is required. However, the above removal method cannot be used for human body biofilms such as skin or scalp. In addition, products used in daily life cannot use strong chemicals that can remove biofilm due to safety issues.

Accordingly, much research is being conducted to develop methods that are safer and more effective for the human body in removing biofilm.

Cutibacterium acnes (C.acnes), also called Propionibacterium acnes, is a bacteria that resides in the skin, conjunctiva, external ear, pharynx, and female urinary tract. It is a skin-dominant bacteria that exists in more than 80% of facial pores and sebaceous glands, and is also a (mutual) commensal bacteria (Sci Rep. 2016; 6: 36062, Br J Dermatol. 2008 Mar. 158(3):442-455). It is also a cause of acne vulgaris.

Acne functional materials such as salicylic acid, benzoyl peroxide, and tetracycline used in acne treatment products also remove symbiotic and beneficial bacteria, raising the risk of microbiome colony collapse/intestinal dysbiosis and causing antibiotic resistance problems. there is.

Against this background, the present inventors have completed the present invention, which is safer and more effective for the human body and can maintain microbiome balance by selectively suppressing harmful bacteria and maintaining strains not related to acne.

One object of the present invention is to provide a composition for controlling biofilm formation of Cutibacterium sp. containing sorbitan caprylate as an active ingredient.

One object of the present invention is to provide a cosmetic composition for controlling biofilm formation of Cutibacterium strains containing sorbitan caprylate as an active ingredient.

One object of the present invention is to provide a quasi-drug composition for controlling biofilm formation of Cutibacterium strains containing sorbitan caprylate as an active ingredient.

Another object of the present invention is to provide a cosmetic composition for maintaining the microbiome balance of Cutibacterium strains containing sorbitan caprylate as an active ingredient.

Hereinafter, the contents of the present invention will be described in detail as follows. Meanwhile, the description and embodiment of one aspect disclosed in the present invention may also be applied to the description and embodiment of other aspects with respect to common matters. Additionally, all combinations of the various elements disclosed in the present invention fall within the scope of the present invention. In addition, the scope of the present invention cannot be considered limited by the specific description described below.

Additionally, it is intended that those skilled in the art may use no more than routine experimentation to include many equivalents to the specific embodiments of the invention described herein that are encompassed by the invention.

One aspect for achieving the above object provides a composition for controlling biofilm formation of Cutibacterium sp. containing sorbitan caprylate as an active ingredient.

The term of the present invention, “Sorbitan caprylate”, is an ester combination of sorbitol and caprylic acid. It is used to create an emulsion in the form of oil in water, which is a form of pure dispersion of oil in water. In addition, sorbitan caprylate helps with preservatives and thus plays a role in lowering the concentration or dosage of preservatives.

In the present invention, sorbitan caprylate can selectively control the biofilm of Cutibacterium acnes depending on the strain, but is not limited thereto.

The term of the present invention, “Cutibacterium sp.”, is a genus of Gram-positive, anaerobic, irregularly shaped bacteria. “Cutibacterium acnes (C.acnes)” of the present invention, also called Propionibacterium acnes, is an anaerobic or aerotolerant bacterium that is non-motile and capable of carbohydrate fermentation. . It lives by breaking down fatty acids secreted by the sebaceous glands of hair follicles, and generally causes acne in young people or acts as an opportunistic infection. In particular, since beneficial and harmful bacteria are distinguished on the skin depending on the genetic type, it is necessary to selectively control them as needed.

The term “RT (ribotype)” of the present invention refers to the nucleic acid sequence (16S rDNA) of the 16S ribosomal subunit of the strain, and C. acnes is divided into several strains depending on the gene type (ribotype). For example, it may be RT1, RT2, RT3, RT4, RT5, RT7, RT8, RT9 or RT10, but is not limited thereto. In one embodiment of the present invention, C.acnes was classified into common bacteria, beneficial bacteria, and harmful bacteria based on gene type, depending on the ratio found in acne skin compared to healthy skin (Am J Clin Dermatol. 2019 Jun; 20(3) : 335-344, J Invest Dermatol. 2013 Sep; 133(9): 2152-2160).

The term “resident flora” of the present invention refers to microorganisms (bacteria) present in the human body that are shared by many people and do not exhibit pathogenicity. Basically, they do not affect human health and are in a symbiotic relationship. However, it can also cause opportunistic infections due to decreased immunity.

“Dominant bacteria” are bacteria that are the most numerous or occupy the largest area within a certain community, and are also called dominant species.

“Symbiotic bacteria” are microorganisms that maintain a close physical relationship with a living animal, plant, or microbial host and coexist (symbiotically) without causing disease in the host. Depending on the type of interaction with the host, the related microorganism is a convenient symbiotic bacteria. It is divided into commensal and symbiont.

The commensal bacteria, dominant bacteria, and symbiotic bacteria may be a strain having the RT1 (ribotype 1) genotype of Cutibacterium acnes, and specifically, may be Cutibacterium acnes ATCC6919, but are not limited thereto. In the present invention, dominant bacteria and commensal bacteria can be used interchangeably with commensal bacteria.

The term “beneficial bacteria” of the present invention enhances skin defense by enhancing the skin regeneration effect and promotes skin regeneration by destroying (killing) the cell membrane and inhibiting the growth of harmful bacteria. In addition, it suppresses the expression of inflammatory factors to soothe the skin and strengthen the skin barrier, increases skin moisture content and suppresses moisture loss, and helps maintain skin homeostasis by improving the pH environment by making the skin pH slightly acidic. The state refers to the strain. The beneficial bacteria may be, for example, a strain having the RT6 (ribotype 6) genotype of Cutibacterium acnes, and specifically, may be Cutibacterium acnes HL110PA3, but is not limited thereto.

As used herein, the term “harmful bacteria” refers to bacteria that cause inflammatory reactions or acne on the skin. The skin harmful bacteria may be, for example, a strain having a genotype of RT4 (ribotype 4) or RT5 (ribotype 5) of Cutibacterium acnes, and specifically, it may be Cutibacterium acnes HL053PA1 or HL043PA1. , but is not limited to this.

In the present invention, the term “biofilm” refers to a membrane-shaped structure formed by microorganisms. It is a well-organized microbial system consisting of a layer of microbial cells connected to the surface and has complex structural and functional characteristics. Biological membranes have physical and chemical gradients that influence microbial metabolic processes. Cells that form biofilms are more than 1,000 times more resistant to antibiotics than floating cells, and biofilm formation is reported to play an important role in the pathogenesis of various diseases.

In the present invention, the term “controlling biofilm formation” means maintaining, enhancing, suppressing, or eliminating biofilm production by microorganisms. Biofilm is a type of protective film created by bacteria, and controlling biofilm formation is directly related to the survival of bacteria.

As used herein, the term “selective regulation” refers to selectively maintaining, enhancing or suppressing a biofilm. In other words, selectively controlling the biofilm may mean selectively suppressing the biofilm of skin harmful bacteria or selectively maintaining or strengthening the biofilm of skin beneficial bacteria, but is not limited to this. By selectively controlling biofilm formation, skin-improving effects and microbiome balance can be maintained by selectively suppressing only harmful bacteria while maintaining beneficial bacteria beneficial to the skin, but is not limited to this.

In one embodiment of the present invention, when applying sorbitan caprylate, the biofilm formation rate of resident bacteria was similar to the control group, and while the biofilm formation of harmful bacteria was suppressed, the biofilm formation of beneficial bacteria was confirmed to significantly increase. (Table 1).

In addition, when applying preservative materials, materials with antibacterial properties, or surfactants (emulsifiers) commonly used in skin compositions, there is no selective control effect on harmful and beneficial bacteria, while Sorbitan Carplate has less harmful bacteria than common/beneficial bacteria. It was confirmed that it inhibits biofilm formation only (Table 2, Table 3, Table 4), and it was confirmed that sorbitan caprylate is excellent as a composition that selectively inhibits only the biofilm of harmful bacteria.

Another aspect of the present invention provides a cosmetic composition for controlling biofilm formation of Cutibacterium strains containing sorbitan caprylate as an active ingredient.

“Sorbitan caprylate”, “Cutibacterium”, “biofilm”, and “biofilm formation control” are the same as described above.

As the term of the present invention, “cosmetic composition” refers to solution, external ointment, cream, foam, nutritional lotion, softening lotion, perfume, pack, softening water, emulsion, makeup base, essence, soap, liquid cleanser, bath additive, sunscreen cream, It may be a formulation selected from the group consisting of sun oils, suspensions, emulsions, pastes, gels, lotions, powders, soaps, surfactant-containing cleansers, oils, powder foundations, emulsion foundations, wax foundations, patches and sprays. , but is not limited to this.

The cosmetic composition of the present invention may further include one or more cosmetically acceptable carriers that are blended with general skin cosmetics, and common ingredients include, for example, oil, water, surfactant, moisturizer, lower alcohol, thickener, Chelating agents, pigments, preservatives, fragrances, etc. may be appropriately mixed, but are not limited thereto.

Cosmetically acceptable carriers included in the cosmetic composition of the present invention vary depending on the formulation of the cosmetic composition.

When the cosmetic formulation of the present invention is an ointment, paste, cream, or gel, the carrier ingredients include animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, and oxidation. Zinc, etc. may be used, but are not limited thereto. These may be used alone or in combination of two or more types.

When the formulation of the present invention is a solution or emulsion, a solvent, solubilizing agent, or emulsifying agent may be used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, Propylene glycol, 1,3-butyl glycol oil, etc. can be used, especially cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil, glycerol aliphatic esters, polyethylene glycol or fatty acid esters of sorbitan. may be used, but is not limited thereto. These may be used singly or two or more types may be used.

When the formulation of the present invention is a suspension, the carrier components include water, liquid diluents such as ethanol or propylene glycol, suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, and miso. Crystalline cellulose, aluminum metahydroxide, bentonite, agar, or tracant may be used, but are not limited thereto. These may be used alone or in combination of two or more types.

When the formulation of the present invention is a soap, alkali metal salts of fatty acids, fatty acid hemiester salts, fatty acid protein hydrolyzates, isethionates, lanolin derivatives, fatty alcohols, vegetable oils, glycerol, sugars, etc. may be used as carrier ingredients. However, it is not limited to this. These may be used alone or in combination of two or more types.

When the formulation of the present invention is a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silcate, polyamide powder, or mixtures thereof may be used as the carrier ingredient, and especially in the case of a spray, chloro May contain propellants such as fluorohydrocarbons, propane/butane or dimethyl ether.

Meanwhile, all ingredients described in the present invention may be included in the composition of the present invention within a range that does not exceed the maximum usage level specified in the Regulations on Cosmetic Safety Standards, etc. and the Chinese 'Cosmetic Safety and Technology Code'.

In one embodiment of the present invention, in order to confirm whether it is legal as a cosmetic composition, pentylene glycol, a cosmetic raw material, is mixed as a preservative with antibacterial activity, and sorbitan caprylate/pentylene glycol is mixed. It was confirmed that only the biofilm of harmful bacteria was selectively inhibited (Table 5). In addition, when mixing sorbitan caprylate and general cosmetic ingredients, it was confirmed that biofilm formation was suppressed only by harmful bacteria compared to common bacteria (RT1)/beneficial bacteria (Table 7), and sorbitan caprylate/pentylene glycol And it was confirmed that it suppresses the biofilm formation of harmful bacteria (RT4, RT5) compared to common bacteria (RT1) even when mixing common cosmetic ingredients, confirming that it is excellent as a cosmetic composition (Table 8).

Another aspect of the present invention provides a quasi-drug composition for controlling biofilm formation of Cutibacterium strains containing sorbitan caprylate as an active ingredient.

“Sorbitan caprylate”, “Cutibacterium”, “biofilm”, and “biofilm formation control” are the same as described above.

The term “quasi-drug” in the present invention refers to products that have a milder effect than pharmaceuticals among products used for the purpose of diagnosing, treating, improving, alleviating, treating, or preventing diseases in humans or animals. For example, quasi-drugs under the Pharmaceutical Affairs Act exclude products used for pharmaceutical purposes and include products used to treat or prevent diseases in humans and animals, and products that have a mild or no direct effect on the human body.

Specifically, the quasi-drugs may include external skin preparations and personal hygiene products. More specifically, it may be a disinfectant cleaner, shower foam, garnish, wet tissue, detergent soap, hand wash, or ointment, but is not limited thereto.

When using the composition according to the present invention as a quasi-drug additive, the composition can be added as is or used together with other quasi-drugs or quasi-drug components, and can be used appropriately according to conventional methods. The mixing amount of the active ingredient can be appropriately determined depending on the purpose of use.

Another aspect of the present invention provides a food composition for controlling biofilm formation of Cutibacterium strains containing sorbitan caprylate as an active ingredient.

“Sorbitan caprylate”, “Cutibacterium”, “biofilm”, and “biofilm formation control” are as described above.

The term "food" in the present invention refers to meat, sausages, bread, chocolate, candies, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages, It includes all foods in the conventional sense, such as vitamin complexes and health functional foods, and is not limited thereto, as long as it can contain the sorbitan caprylate of the present invention. In addition, it can be manufactured by adding sorbitan caprylate according to the present invention to juices, teas, jellies, juices, etc. manufactured using sorbitan caprylate as a main ingredient, and may include forms such as pills, powders, granules, preparations, tablets, capsules, or liquids. You can.

When manufacturing the food composition, it can be manufactured by adding raw materials and ingredients commonly added in the art, and the types are not particularly limited. For example, like regular foods, it may include various herbal extracts, foodologically acceptable food additives, or natural carbohydrates as additional ingredients, but is not limited thereto. The mixing amount of the active ingredients can be appropriately determined depending on the purpose of use. Since the composition of the present invention uses extracts derived from natural products as the active ingredient, there is no problem in terms of stability, so there is no significant limitation on the mixing amount.

Another aspect of the present invention provides a cosmetic or quasi-drug composition for maintaining the microbiome balance of a Cutibacterium strain containing sorbitan caprylate as an active ingredient.

“Sorbitan caprylate”, “cosmetic composition”, and “quasi-drug” are the same as described above.

The term “microbiome” of the present invention refers to the entire genetic information of microorganisms inhabiting the human body or the microorganisms themselves. Microbiota and genome (Microbiome), which are microorganisms that inhabit and coexist in the human body It is a compound word of Genome.

The term “microbiome balance” of the present invention refers to maintaining the microbiome balance, and the balance of the microbiome can be maintained by promoting the growth of beneficial bacteria while suppressing the growth of harmful bacteria, and the microbiome balance is If it breaks down, the skin barrier becomes weak, making it easier for harmful microorganisms to proliferate. Specifically, the microbiome balance may be the microbiome balance of the skin, or the microbiome balance of the Cutibacterium strain, but is not limited thereto.

The sorbitan caprylate of the present invention can maintain the balance of the microbiome by maintaining or strengthening the biofilm of beneficial bacteria while suppressing the biofilm of harmful bacteria, but is not limited to this.

The present invention relates to a composition containing sorbitan caprylate as an active ingredient. The composition maintains the skin microbiome balance by controlling the biofilm formation of Cutibacterium strains, thereby improving skin condition while being safe for the skin. It can be used as an excellent cosmetic composition and quasi-drug composition.

Figure 1 is a graph comparing the biofilm formation rate for each Cutibacterium acnes strain when treated with 0.05% sorbitan caprylate.
Figure 2 is a graph comparing the biofilm formation rate for each Cutibacterium acnes strain when treated with 0.1% sorbitan caprylate.
Figure 3 is a graph comparing the biofilm formation rate for each Cutibacterium acnes strain when processing preservative materials.
Figure 4 is a graph comparing the biofilm formation rate for each Cutibacterium acnes strain when processing a material having antibacterial properties.
Figure 5 is a graph comparing the biofilm formation rate for each Cutibacterium acnes strain when processing mixed raw materials of sorbitan caprylate and pentylene glycol.
Figure 6 is a graph comparing the biofilm formation rate by Cutibacterium acnes strain when treating lotion with mixed raw materials of sorbitan caprylate and pentylene glycol.
Figure 7 is a graph showing the effect of selectively suppressing only the biofilm of harmful bacteria Cutibacterium acnes when treating lotion with mixed raw materials of sorbitan caprylate and pentylene glycol.

Hereinafter, the present invention will be described in more detail through examples. However, these examples are for illustrative purposes only and the scope of the present invention is not limited to these examples.

Experimental Example 1. Selection and cultivation of Cutibacterium acnes (C.acnes) strains

C. acnes strains that were associated with causing acne were selected based on their gene type (ribotype, RT). Four species were prepared: ATCC6919 (C.acnes RT1), HL053PA1 (C.acnes RT4), HL043PA1 (C.acnes RT5), and HL110PA3 (C.acnes RT6), and anaerobic conditions were performed for each C.acnes strain (by RT). It was cultured in RCM liquid medium that had been sterilized (121°C, 2 atmospheres, 15 minutes in an autoclave).

In order to set the OD value of the four cultured strains to 0.03, the bacteria were diluted so that the culture had an OD ₆₀₀ of 0.03, and 0.9 ml of each was seeded into a 24 well plate. 0.1 ml each was dispensed into a 24 well plate according to the test group sample concentration. For the control group, 0.1 ml each of sterilized purified water (DW) was dispensed instead of the sample. To mix the strain and sample, the samples were incubated at 300 rpm in a shaking incubator. It was carried out for 30 minutes. Cultured in a closed container under anaerobic conditions for 60 to 84 hours (about 72 hours).

Experimental Example 2. Sample preparation

The sample (sorbitan caprylate) was weighed and mixed in sterilized purified water (water), voltexed, and homogenized for testing. During the formulation application experiment, the sample was mixed with the sterilized formulation, voltexed, and then homogenized.

Experimental Example 3. Test of biofilm formation inhibition effect

As a biofilm was formed on the bottom of the plate, the supernatant was removed from the plate and washed once with sterilized purified water. Biofilm was stained by loading 1ml of 0.05% CV dye (crystal violet) and reacting for 20 minutes. After removing the dye, it was washed once with sterilized purified water, and 1 ml of 20% acetic acid was loaded for the purpose of eluting the CV dye, and carried out in a shaking incubator at 300 rpm for 30 minutes. The elution amount of CV dye was quantified by measuring the absorbance (OD ₅₄₅ ) at 545 nm using a spectrophotometer, and the absorbance values of the control and experimental groups were calculated to evaluate/compare the inhibition of biofilm formation.

Example 1. Confirmation of biofilm formation when applying sorbitan caprylate material

When applying sorbitan caprylate 0.05% or 0.1%, the absorbance (OD ₅₄₅ ) was measured at 545 nm using a spectrophotometer after staining with CV dye to check whether biofilm was formed, through which biofilm was formed. Inhibition was confirmed (Table 1).

As shown in Table 1, when 0.05% sorbitan caprylate was applied, the biofilm formation rate in RT1, a symbiotic bacteria of C. acnes, was similar to the control group (biofilm formation rate 100%), and the rate of biofilm formation was similar to that of the control group (100% biofilm formation rate). In RT5, the formation rate was reduced by about two times compared to the control group, suppressing biofilm formation, and in RT6, a beneficial bacteria, the formation rate was increased by about two times compared to the control group, confirming that biofilm formation was strengthened (Figure 1).

When 0.1% sorbitan caprylate was applied, biofilm formation was similar to the control group at RT1, biofilm formation was suppressed by about 10 times less than the control group at RT5, and biofilm formation was confirmed to be similar to that of the control group at RT6. (Figure 2).

Through this, it was confirmed that sorbitan caprylate does not affect the biofilm formation of flora and fauna and can selectively inhibit the formation of biofilms of harmful bacteria while strengthening/maintaining the biofilm of beneficial bacteria.

Example 2. Comparison of inhibition of biofilm formation when applying preservative materials, antibacterial materials, or surfactants (emulsifiers)

Example 2-1. Comparison of inhibition of biofilm formation when applying preservative materials

Three types of raw materials commonly used in skin compositions, glyceryl caprylate, octanediol, and hexanediol, were selected as comparison groups, and 0.05% sample was applied to the strain to measure absorbance (OD ₅₄₅ ). ) was measured, and the inhibition of biofilm formation was compared (Table 2).

As shown in Table 2 above, the biofilm formation rate of harmful bacteria (RT5) in the comparison group was similar to the control group, and the biofilm formation rate of beneficial bacteria (RT6) was reduced or similar, and the comparison group was selective for harmful and beneficial bacteria. It was confirmed that there was no control effect.

On the other hand, in the test group (Sorbitan caprylate), the RT5 biofilm formation rate decreased and the RT6 biofilm formation rate significantly increased. In particular, biofilm formation was suppressed only in harmful bacteria compared to common bacteria (RT1)/beneficial bacteria. It was confirmed that tan caprylate has an excellent effect in selectively controlling biofilm formation of harmful bacteria (FIG. 3).

Example 2-2. Comparison of inhibition of biofilm formation when applying antibacterial materials

The antibacterial materials that control the formation of biofilm include four types of antibacterial materials (totarol), antibacterial plant extracts (BHC-C, golden extract, Lactobacillus ferment, licorice root extract, and Militaris Cordyceps sinensis mycelium extract mixture), Metal antibacterial material (Sepitonic M3, Zn/Cu) and antibacterial lactic acid bacteria fermentation product (lactophorin, Lactobacillus fermentation filtrate) were selected, and 0.3% sample was applied to the strain to measure absorbance (OD ₅₄₅₎ , through which bio Film formation inhibition was compared (Table 3).

As shown in Table 3, the antibacterial material (totarol) had a lower biofilm formation rate compared to the control group in RT1, RT5, and RT6. It was confirmed that there was no effect on the biofilm formation rate of harmful bacteria (RT5) of the antibacterial plant extract, and that the biofilm formation rate of beneficial bacteria (RT6) was significantly reduced, and that the RT5 and The biofilm formation rate of RT6 was similar to that of the control group. Therefore, unlike sorbitan caprylate, it was confirmed that the four materials previously known to have antibacterial properties did not have selective biofilm formation inhibitory activity against harmful bacteria (FIG. 4).

Example 2-3. Comparison of surfactant (emulsifier) inhibition of biofilm formation

Comparison of four representative surfactants (emulsifiers) used in skin compositions: Sorbitan Stearate, PEG-based (PEG-40 Hydrogenated Castor Oil), Polyglyceryl-4 Caprylate, and Hydrogenated Lecithin. Groups were selected, and 0.05% samples were applied to the strains to compare whether biofilm formation was inhibited (Table 4).

As shown in Table 4 above, in the comparison group, the biofilm formation rate of PEG-based harmful bacteria (RT4) increased by more than three times compared to the control group, and polyglyceryl-based and lecithin-based bacteria increased by more than 3 times compared to the control group. The biofilm formation rate was significantly reduced compared to the control group.

On the other hand, in the test group (sorbitan caprylate), the formation rate of RT4 and RT5 biofilms, which are harmful bacteria, decreased, and the rate of RT6 biofilm formation significantly increased. In particular, biofilm formation was suppressed only in harmful bacteria compared to common/beneficial bacteria. It was confirmed that sorbitan caprylate is effective in selectively controlling the biofilm formation of harmful bacteria.

Example 3. Evaluation of the legality of sorbitan caprylate as a cosmetic composition

Example 3-1. Testing the effect of inhibiting biofilm formation when sorbitan caprylate is used simultaneously with cosmetic raw materials

Pentylene glycol, a cosmetic raw material, was selected as a preservative with antibacterial activity, and the biofilm formation rate was measured when used simultaneously with sorbitan caprylate.

A mixture of 0.1% sorbitan caprylate and 0.2% pentylene glycol was applied to the strain, the absorbance (OD ₅₄₅ ) was measured, and the inhibition of biofilm formation was compared (Table 5).

As shown in Table 5, the biofilm formation rate of harmful bacteria (RT5) of sorbitan caprylate/pentylene glycol decreased by about 5 times compared to the control group, and the biofilm formation rate of beneficial bacteria (RT6) was 2 times that of the control group. As it increased, it was confirmed that only the biofilm of harmful bacteria was selectively suppressed in the caprylate/pentylene glycol mixed raw material (FIG. 5).

Example 3-2. Testing the effect of inhibiting biofilm formation when applied to lotion formulation of sorbitan caprylate/pentylene glycol

In order to use the sorbitan caprylate/pentylene glycol mixed raw material in a general lotion formulation, general lotion raw materials were mixed (Table 6).

0.2% sorbitan caprylate was applied to the strain in a cosmetic lotion formulation (test group 1), the absorbance (OD ₅₄₅ ) was measured, and through this, the inhibition of biofilm formation was compared (Table 7), and 0.3% sorbitan was added to the strain. Caprylate/pentylene glycol was applied to the lotion formulation (test group 2), the absorbance (OD ₅₄₅ ) was measured, and the inhibition of biofilm formation was compared (Table 8).

As shown in Table 7 above, when applying sorbitan caprylate lotion to strains, it was confirmed that biofilm formation was suppressed only in harmful bacteria compared to common bacteria (RT1)/beneficial bacteria in test group 1 (FIG. 6).

In addition, when applying sorbitan caprylate/pentylene glycol lotion to the strains, it was confirmed that biofilms of harmful bacteria RT4 and RT5 were selectively inhibited in test group 2 (FIG. 7).

From the above description, those skilled in the art to which the present invention pertains will understand that the present invention can be implemented in other specific forms without changing its technical idea or essential features. In this regard, the embodiments described above should be understood in all respects as illustrative and not restrictive. The scope of the present invention should include the meaning and scope of the patent claims described below rather than the detailed description above, and all changes or modified forms derived from the equivalent concept thereof.

Claims (10)

A composition for controlling biofilm formation of Cutibacterium sp., comprising sorbitan caprylate as an active ingredient.
The composition according to claim 1, wherein the strain of the genus Cutibacterium is Cutibacterium acnes (C.acnes).
The composition according to claim 2, wherein the Cutibacterium acnes is a skin flora and is a strain having a genotype of RT1 (ribotype 1).
The composition according to claim 2, wherein the Cutibacterium acnes is a skin beneficial bacteria and is a strain having a genotype of RT6 (ribotype 6).
The composition according to claim 2, wherein the Cutibacterium acnes is a skin-harmful bacterium and is a strain having a genotype of RT4 (ribotype 4) or RT5 (ribotype 5).
The composition of claim 4, wherein the sorbitan caprylate selectively maintains or strengthens the biofilm of beneficial skin bacteria.
The composition of claim 5, wherein the sorbitan caprylate selectively inhibits biofilm of harmful skin bacteria.
The composition according to claim 1, wherein the composition is a cosmetic composition.
The composition of claim 1, wherein the composition is a quasi-drug composition.
A cosmetic composition for maintaining the microbiome balance of a Cutibacterium strain containing sorbitan caprylate as an active ingredient.